South Texas Accelerated Research Therapeutics START

San Antonio, Texas 98229

8 studies enrolling now · 43 studies all time

What they study most

Advanced Breast Cancer, Advanced Cancer, Advanced Gastric Cancer, Advanced Malignancies, Advanced Nonhematologic Malignancies, Advanced Nonhematological Malignancies, Advanced Nonsmall Cell Lung Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Astrocytoma, Grade III, B-Cell Chronic Lymphocytic Leukemia, Biliary Tract Neoplasms

Studies at this site

• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors — Recruiting now
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — Recruiting now
• A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma — Recruiting now
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC — Recruiting now
• A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors — Recruiting now
• A Study of PHST001 in Advanced Solid Tumors — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) — Recruiting now
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors — Stopped early
• A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer — Running, not enrolling
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) — Running, not enrolling
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors — Stopped early
• Study of Oral MRT-2359 in Selected Cancer Patients — Running, not enrolling
• A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread — Running, not enrolling
• A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors — Completed
• BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab — Completed
• BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab — Completed
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors — Completed
• FS120 Phase 1/1b Study in Patients With Advanced Malignancies — Running, not enrolling
• Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers — Completed
• Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) — Running, not enrolling
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma — Completed
• Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies — Completed
• A Study of PNT2258 in Patients With Advanced Solid Tumors — Completed
• A Study of PLX2853 in Advanced Malignancies. — Completed
• Study of FCN-437c in Patients With Advanced Solid Tumors — Completed
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) — Stopped early
• Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 — Completed
• First in Human Trial of TAS266 in Patients With Advanced Solid Tumors — Stopped early
• A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers — Completed
• First-in-Human Study of MS201408-0005A as Single Agent and in Combinations — Stopped early
• Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors — Completed
• Sym004 in Patients With Advanced Solid Tumors — Completed
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma — Completed
• Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors — Completed
• Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors — Withdrawn before enrolling
• Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies — Stopped early
• Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies — Withdrawn before enrolling
• Study of NMS-1116354 in Solid Tumors — Stopped early
• Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors — Completed
• Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia — Withdrawn before enrolling